mRNA疫苗非病毒载体递送系统研究进展<sup>*</sup>

doi:10.13523/j.cb.2205051

中国生物工程杂志

2022, Vol. 42

Issue (9): 58-66 DOI: 10.13523/j.cb.2205051

综述

mRNA疫苗非病毒载体递送系统研究进展^*

金喆彤¹,芮雪¹,姜侯喆¹,王晶晶^1,^**(

),陈玉根²

1.南京中医药大学药学院南京 210046
2.南京中医药大学附属医院南京 210029

Research Progress of Non-viral Vector Delivery System for mRNA Vaccines

JIN Zhe-tong¹,RUI Xue¹,JIANG Hou-zhe¹,WANG Jing-jing^1,^**(

),CHEN Yu-gen²

1. College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210046, China
2. The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China

全文: PDF(982 KB) HTML

摘要：

新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)疫情的暴发导致全球迫切需要大量有效的疫苗来应对。mRNA疫苗具有良好的安全性,且研发周期短,成为目前最有潜力的疫苗之一,在传染病和肿瘤研究领域也引发了更多关注。随着技术创新,mRNA不稳定性、翻译效率低等缺点得到较大改善。如何安全高效地将mRNA递送至靶细胞仍是阻碍mRNA研究的一大挑战。综述目前应用于mRNA疫苗体内递送的非病毒载体递送系统,以及mRNA在传染病疫苗和肿瘤疫苗中的应用现状,旨在为mRNA疫苗研发提供参考。

关键词： mRNA疫苗; 非病毒载体; 递送系统; 脂质纳米粒; 聚合物

Abstract:

With the outbreak of COVID-19, the world urgently needs a large number of effective vaccines to deal with this disaster. mRNA vaccines are safe and have short development cycle, which can fill the gap between epidemic diseases and vaccine shortages. So mRNA has become one of the most potential vaccines at present and has attracted attention in the field of infectious diseases and tumors. Technological innovation has greatly improved the shortcomings of mRNA, such as instability and low translation efficiency. However, delivering mRNA to target cells safely and efficiently is still a major challenge that hinders the progress in mRNA research. Hopefully, delivery systems have put forward many effective solutions. This review focuses on the non-viral vector delivery system for mRNA vaccine delivery in vivo, and the application of mRNA in infectious disease and tumor vaccine, in order to provide reference for research and development of mRNA vaccines.

Key words: mRNA vaccine Non-viral vector Delivery system Lipid nanoparticles Polymer

收稿日期: 2022-05-30 出版日期: 2022-10-10

ZTFLH:

R94R186

基金资助: * 国家自然科学基金(32000997);江苏省高等学校自然科学研究基金(20KJB350004)

通讯作者: 王晶晶 E-mail: wangjingjing@njucm.edu.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	金喆彤
	芮雪
	姜侯喆
	王晶晶
	陈玉根

引用本文:

金喆彤,芮雪,姜侯喆,王晶晶,陈玉根. mRNA疫苗非病毒载体递送系统研究进展^*[J]. 中国生物工程杂志, 2022, 42(9): 58-66.

JIN Zhe-tong,RUI Xue,JIANG Hou-zhe,WANG Jing-jing,CHEN Yu-gen. Research Progress of Non-viral Vector Delivery System for mRNA Vaccines. China Biotechnology, 2022, 42(9): 58-66.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2205051 或 https://manu60.magtech.com.cn/biotech/CN/Y2022/V42/I9/58

图1 应用于RNA疫苗的非病毒载体递送系统

表1 中国进入临床试验阶段的COVID-19 mRNA疫苗

表2 针对传染性疾病的mRNA疫苗

表3 BioNTech、Moderna和CureVac公司的mRNA肿瘤疫苗研究进展

[1]	孟子延, 马丹婧, 高雪, 等. mRNA疫苗及其作用机制的研究进展. 中国生物制品学杂志, 2021, 34(6): 740-744.
	Meng Z Y, Ma D J, Gao X, et al. Progress in research on mRNA vaccine and its mechanism. Chinese Journal of Biologicals, 2021, 34(6): 740-744.
[2]	Granot-Matok Y, Kon E, Dammes N, et al. Therapeutic mRNA delivery to leukocytes. Journal of Controlled Release, 2019, 305: 165-175. doi: S0168-3659(19)30288-3 pmid: 31121277
[3]	Iavarone C, O’hagan D T, Yu D, et al. Mechanism of action of mRNA-based vaccines. Expert Review of Vaccines, 2017, 16(9): 871-881. doi: 10.1080/14760584.2017.1355245 pmid: 28701102
[4]	Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Molecular Cancer, 2021, 20(1): 41. doi: 10.1186/s12943-021-01335-5 pmid: 33632261
[5]	Karikó K, Muramatsu H, Welsh F A, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy, 2008, 16(11): 1833-1840. doi: 10.1038/mt.2008.200 pmid: 18797453
[6]	Hao L, Wu Y Q, Zhang Y D, et al. Combinational PRR agonists in liposomal adjuvant enhances immunogenicity and protective efficacy in a tuberculosis subunit vaccine. Frontiers in Immunology, 2020, 11: 575504. doi: 10.3389/fimmu.2020.575504
[7]	Karikó K, Ni H P, Capodici J, et al. mRNA is an endogenous ligand for toll-like receptor 3. Journal of Biological Chemistry, 2004, 279(13): 12542-12550. doi: 10.1074/jbc.M310175200 pmid: 14729660
[8]	Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 2004, 303(5663): 1526-1529. doi: 10.1126/science.1093620 pmid: 14976262
[9]	Wang H X, Li M Q, Lee C M, et al. CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chemical Reviews, 2017, 117(15): 9874-9906. doi: 10.1021/acs.chemrev.6b00799
[10]	Weissman D. mRNA transcript therapy. Expert Review of Vaccines, 2015, 14(2): 265-281. doi: 10.1586/14760584.2015.973859 pmid: 25359562
[11]	Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics-developing a new class of drugs. Nature Reviews Drug Discovery, 2014, 13(10): 759-780. doi: 10.1038/nrd4278 pmid: 25233993
[12]	Hajj K A, Whitehead K A. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nature Reviews Materials, 2017, 2: 17056. doi: 10.1038/natrevmats.2017.56
[13]	胡瞬, 易有金, 胡涛, 等. mRNA疫苗的开发及临床研究进展. 中国生物工程杂志, 2019, 39(11): 105-112.
	Hu S, Yi Y J, Hu T, et al. Development and clinical progress of mRNA vaccine. China Biotechnology, 2019, 39(11): 105-112.
[14]	Karikó K, Muramatsu H, Ludwig J, et al. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Research, 2011, 39(21): e142. doi: 10.1093/nar/gkr695
[15]	Li N, Hu Y L, He C X, et al. Preparation, characterisation and anti-tumour activity of Ganoderma lucidum polysaccharide nanoparticles. Journal of Pharmacy and Pharmacology, 2010, 62(1): 139-144. doi: 10.1211/jpp.62.01.0016
[16]	Andries O, Mc Cafferty S, de Smedt S C, et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. Journal of Controlled Release: Official Journal of the Controlled Release Society, 2015, 217: 337-344. doi: 10.1016/j.jconrel.2015.08.051
[17]	Pardi N, Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods in Molecular Biology (Clifton, N J), 2017, 1499: 109-121.
[18]	Anderson B R, Muramatsu H, Nallagatla S R, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Research, 2010, 38(17): 5884-5892. doi: 10.1093/nar/gkq347 pmid: 20457754
[19]	Kamimura K, Suda T, Zhang G S, et al. Advances in gene delivery systems. Pharmaceutical Medicine, 2011, 25(5): 293-306. doi: 10.2165/11594020-000000000-00000 pmid: 22200988
[20]	Nguyen G N, Everett J K, Kafle S, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nature Biotechnology, 2021, 39(1): 47-55. doi: 10.1038/s41587-020-0741-7 pmid: 33199875
[21]	Shirley J L, de Jong Y P, Terhorst C, et al. Immune responses to viral gene therapy vectors. Molecular Therapy, 2020, 28(3): 709-722. doi: S1525-0016(20)30002-2 pmid: 31968213
[22]	Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. Journal of Clinical and Diagnostic Research, 2015, 9(1): GE01-GE06.
[23]	Hou X C, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 2021, 6(12): 1078-1094. doi: 10.1038/s41578-021-00358-0
[24]	Tros de Ilarduya C, Sun Y, Düzgüneᶊ N. Gene delivery by lipoplexes and polyplexes. European Journal of Pharmaceutical Sciences, 2010, 40(3): 159-170. doi: 10.1016/j.ejps.2010.03.019 pmid: 20359532
[25]	Ulkoski D, Bak A, Wilson J T, et al. Recent advances in polymeric materials for the delivery of RNA therapeutics. Expert Opinion on Drug Delivery, 2019, 16(11): 1149-1167. doi: 10.1080/17425247.2019.1663822
[26]	Zhong D G, Jiao Y P, Zhang Y, et al. Effects of the gene carrier polyethyleneimines on structure and function of blood components. Biomaterials, 2013, 34(1): 294-305. doi: 10.1016/j.biomaterials.2012.09.060 pmid: 23069714
[27]	Dahlman J E, Barnes C, Khan O F, et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nature Nanotechnology, 2014, 9(8): 648-655. doi: 10.1038/nnano.2014.84 pmid: 24813696
[28]	Tang G P, Guo H Y, Alexis F, et al. Low molecular weight polyethylenimines linked by beta-cyclodextrin for gene transfer into the nervous system. The Journal of Gene Medicine, 2006, 8(6): 736-744. doi: 10.1002/jgm.874
[29]	Venault A, Huang Y C, Lo J W, et al. Tunable PEGylation of branch-type PEI/DNA polyplexes with a compromise of low cytotoxicity and high transgene expression: in vitro and in vivo gene delivery. Journal of Materials Chemistry B, 2017, 5(24): 4732-4744. doi: 10.1039/c7tb01046j pmid: 32264316
[30]	Xue L, Yan Y F, Kos P, et al. PEI fluorination reduces toxicity and promotes liver-targeted siRNA delivery. Drug Delivery and Translational Research, 2021, 11(1): 255-260. doi: 10.1007/s13346-020-00790-9
[31]	Ren J, Cao Y M, Li L, et al. Self-assembled polymeric micelle as a novel mRNA delivery carrier. Journal of Controlled Release, 2021, 338: 537-547. doi: 10.1016/j.jconrel.2021.08.061 pmid: 34481924
[32]	Li M, Li Y, Peng K, et al. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. Acta Biomaterialia, 2017, 64: 237-248. doi: S1742-7061(17)30635-9 pmid: 29030308
[33]	Liu Y, Li Y F, Keskin D, et al. Poly(β-amino esters): synthesis, formulations, and their biomedical applications. Advanced Healthcare Materials, 2019, 8(2): e1801359.
[34]	Patel A K, Kaczmarek J C, Bose S M, et al. Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium. Advanced Materials (Deerfield Beach, Fla), 2019, 31(8): e1805116.
[35]	Dong Y Z, Siegwart D J, Anderson D G. Strategies, design, and chemistry in siRNA delivery systems. Advanced Drug Delivery Reviews, 2019, 144: 133-147. doi: S0169-409X(19)30054-7 pmid: 31102606
[36]	Cullis P R, Hope M J. Lipid nanoparticle systems for enabling gene therapies. Molecular Therapy, 2017, 25(7): 1467-1475. doi: S1525-0016(17)30111-9 pmid: 28412170
[37]	Cheng X W, Lee R J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Advanced Drug Delivery Reviews, 2016, 99: 129-137. doi: S0169-409X(16)30053-9 pmid: 26900977
[38]	Hirko A, Tang F X, Hughes J A. Cationic lipid vectors for plasmid DNA delivery. Current Medicinal Chemistry, 2003, 10(14): 1185-1193. doi: 10.2174/0929867033457412
[39]	Colosimo A, Serafino A, Sangiuolo F, et al. Gene transfection efficiency of tracheal epithelial cells by DC-Chol-DOPE/DNA complexes. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1999, 1419(2): 186-194. doi: 10.1016/S0005-2736(99)00067-X
[40]	高晓佩, 管晓燕, 白国辉, 等. DNA疫苗的作用机制. 中国组织工程研究, 2018, 22(8): 1281-1286.
	Gao X P, Guan X Y, Bai G H, et al. DNA vaccines: mechanisms of action. Chinese Journal of Tissue Engineering Research, 2018, 22(8): 1281-1286.
[41]	Fenton O S, Kauffman K J, McClellan R L, et al. Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Advanced Materials (Deerfield Beach, Fla), 2016, 28(15): 2939-2943. doi: 10.1002/adma.201505822
[42]	McKinlay C J, Benner N L, Haabeth O A, et al. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115(26): E5859-E5866.
[43]	Heyes J, Palmer L, Bremner K, et al. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. Journal of Controlled Release, 2005, 107(2): 276-287. pmid: 16054724
[44]	Semple S C, Akinc A, Chen J X, et al. Rational design of cationic lipids for siRNA delivery. Nature Biotechnology, 2010, 28(2): 172-176. doi: 10.1038/nbt.1602 pmid: 20081866
[45]	Kauffman K J, Dorkin J R, Yang J H, et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Letters, 2015, 15(11): 7300-7306. doi: 10.1021/acs.nanolett.5b02497 pmid: 26469188
[46]	Dong Y Z, Love K T, Dorkin J R, et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111(11): 3955-3960.
[47]	Rybakova Y, Kowalski P S, Huang Y X, et al. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo. Molecular Therapy, 2019, 27(8): 1415-1423. doi: S1525-0016(19)30226-6 pmid: 31160223
[48]	Scheel B, Teufel R, Probst J, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. European Journal of Immunology, 2005, 35(5): 1557-1566. pmid: 15832293
[49]	Armbruster N, Jasny E, Petsch B. Advances in RNA vaccines for preventive indications: a case study of A vaccine against rabies. Vaccines, 2019, 7(4): 132. doi: 10.3390/vaccines7040132
[50]	Mai Y P, Guo J S, Zhao Y, et al. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cellular Immunology, 2020, 354: 104143. doi: 10.1016/j.cellimm.2020.104143
[51]	Oladimeji O, Akinyelu J, Singh M. Co-polymer functionalised gold nanoparticles show efficient mitochondrial targeted drug delivery in cervical carcinoma cells. Journal of Biomedical Nanotechnology, 2020, 16(6): 853-866. doi: 10.1166/jbn.2020.2930 pmid: 33187581
[52]	Kaczmarek J C, Kauffman K J, Fenton O S, et al. Optimization of a degradable polymer-lipid nanoparticle for potent systemic delivery of mRNA to the lung endothelium and immune cells. Nano Letters, 2018, 18(10): 6449-6454. doi: 10.1021/acs.nanolett.8b02917 pmid: 30211557
[53]	Polack F P, Thomas S J, Kitchin N, et al. Safety and efficacy of the BNT162b 2 mRNA covid-19 vaccine. The New England Journal of Medicine, 2020, 383(27): 2603-2615. doi: 10.1056/NEJMoa2034577
[54]	Baden L R, El Sahly H M, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. Annals of Internal Medicine, 2021, 384(5): 403-416.
[55]	Chen G L, Li X F, Dai X H, et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Microbe, 2022, 3(3): e193-e202. doi: 10.1016/S2666-5247(21)00280-9
[56]	Zhang N N, Li X F, Deng Y Q, et al. A thermostable mRNA vaccine against COVID-19. Cell, 2020, 182(5): 1271-1283,e16. doi: 10.1016/j.cell.2020.07.024
[57]	Bahl K, Senn J J, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Molecular Therapy, 2017, 25(6): 1316-1327. doi: S1525-0016(17)30156-9 pmid: 28457665
[58]	Freyn A W, Ramos da Silva J, Rosado V C, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Molecular Therapy, 2020, 28(7): 1569-1584. doi: S1525-0016(20)30199-4 pmid: 32359470
[59]	Mu Z K, Haynes B F, Cain D W. HIV mRNA vaccines-progress and future paths. Vaccines, 2021, 9(2): 134. doi: 10.3390/vaccines9020134
[60]	Medina-Magües L G, Gergen J, Jasny E, et al. mRNA vaccine protects against zika virus. Vaccines, 2021, 9(12): 1464. doi: 10.3390/vaccines9121464
[61]	Zhang R, Billingsley M M, Mitchell M J. Biomaterials for vaccine-based cancer immunotherapy. Journal of Controlled Release, 2018, 292: 256-276. doi: S0168-3659(18)30579-0 pmid: 30312721
[62]	Rausch S, Schwentner C, Stenzl A, et al. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Human Vaccines & Immunotherapeutics, 2014, 10(11): 3146-3152.
[63]	Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585(7823): 107-112. doi: 10.1038/s41586-020-2537-9
[64]	Schmidt M, Bolte S, Frenzel K, et al. Abstract OT2-06-01: highly innovative personalized RNA-immunotherapy for patients with triple negative breast cancer. Cancer Research, 2019, 79(4_Supplement): OT2-06-01.
[65]	Liu L N, Wang Y H, Miao L, et al. Combination immunotherapy of MUC 1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Molecular Therapy, 2018, 26(1): 45-55. doi: 10.1016/j.ymthe.2017.10.020
[66]	Lin Y X, Wang Y, Ding J X, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Science Translational Medicine, 2021, 13(599): eaba9772. doi: 10.1126/scitranslmed.aba9772

[1]	赵冰,麻淳博,孙冰冰,赵海洋. 智能胰岛素递送系统用于糖尿病治疗的研究进展[J]. 中国生物工程杂志, 2022, 42(5): 81-90.
[2]	井汇源,段二珍,董望. 体外转录的自我复制型mRNA疫苗研究进展^*[J]. 中国生物工程杂志, 2020, 40(12): 25-30.
[3]	刘子儒,张甜. 聚多巴胺改性聚合物在神经修复中的研究进展 ^*[J]. 中国生物工程杂志, 2020, 40(10): 57-64.
[4]	秦思楠,唐录华,高文惠. 恩诺沙星分子印迹电化学传感器的制备及其在食品快速检测中的应用 ^*[J]. 中国生物工程杂志, 2019, 39(3): 65-74.
[5]	胡瞬,易有金,胡涛,李福胜. mRNA疫苗的开发及临床研究进展[J]. 中国生物工程杂志, 2019, 39(11): 105-112.
[6]	郗来顺,云鹏,王元斗,张冠宏,邢泉生,陈阳生,宿烽. 形状记忆聚合物在组织工程中的应用 ^*[J]. 中国生物工程杂志, 2018, 38(12): 76-81.
[7]	周忠厅, 张权, 王胜涛, 蔡颖, 中西秀树, 尹健. 共价连接BODIPY光敏剂的聚合物纳米胶束及其靶向光动力疗效的研究[J]. 中国生物工程杂志, 2017, 37(10): 33-41.
[8]	代爽, 赵青青, 邱峰. PEI-壳聚糖在结肠癌细胞CD133⁺梯度表达的转染研究[J]. 中国生物工程杂志, 2016, 36(6): 32-38.
[9]	罗彦凤刘钊李永刚王远亮. 人脐静脉内皮细胞在D,L-聚乳酸基形状记忆聚合物上的黏附和增殖行为研究[J]. 中国生物工程杂志, 2010, 30(05): 1-5.
[10]	王海,王华茂,李锦军,石必枝,李宗海. 一种靶向性阳离子多肽载体的表达纯化[J]. 中国生物工程杂志, 2007, 27(11): 57-60.
[11]	金科铭,曹学君,庄英萍,储炬,张嗣良. 固定化青霉素酰化酶在光-pH敏感可回用两水相中裂解青霉素G为6-APA[J]. 中国生物工程杂志, 2007, 27(10): 53-58.
[12]	孙恩杰, 杨冬. 非病毒型基因载体研究进展[J]. 中国生物工程杂志, 2004, 24(4): 21-25.
[13]	陈国强, 赵锴. 生物工程与生物材料[J]. 中国生物工程杂志, 2002, 22(5): 1-8.
[14]	肖娟, 陆华中, 邹萍. 树枝状聚合物在生物医学领域的应用进展[J]. 中国生物工程杂志, 2002, 22(4): 6-11.
[15]	. 制造业、生物加工[J]. 中国生物工程杂志, 1998, 18(S1): 29-38.

Viewed

Full text

Abstract

Cited

Shared

Discussed